is semaglutide still on the shortage list As of February 21, 2025, FDA updated its drug list, marking the injection shortage as resolved. Semaglutide injections are no longer classified as “currently in shortage,” and both 503A GLP-1 No Longer on FDA's

Description

Diabetes leads to a significantly accelerated incidence of various related macrovascular complications, including peripheral vascular disease and cardiovascular disease (the most common cause of mortality in diabetes), as well as microvascular complications such as kidney disease and retinopathy

patent describes new glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes type 2, hyperglycemia and obesity.

Originally CD was considered as a malabsorption syndrome of childhood, whereas it is now recognised as a disease which may be diagnosed at any age

GLP-1RAs reduce events linked to atherogenic cardiovascular disease (especially ischemic stroke) and also renal outcomes (FLOW trial with semaglutide), with a limited effect on heart failure

GLP 1 Drug Biosimilar Market segmentation by reference biologic in the GLP-1 drug biosimilar market includes semaglutide biosimilars, liraglutide biosimilars, exenatide biosimilars, and dulaglutide biosimilars.